OBJECTIVES: Blood stem cell mobilization, which is important as a source of hematopoietic stem cells for transplantation, is performed using granulocyte colonystimulating factor (G-CSF), but is ineffective in around 20% of so called poor mobilizers. Combining G-CSF with plerixafor increases the percentage of successful mobilizations. The drug has orphan drug status and is approved for lymphoma and multiple myeloma patients. The objective was to compare the cost-effectiveness of three available mobilization schemes: i) the use of plerixafor "on demand" (POD) even during a first mobilization attempt in all patients who show inadequate response, ii) the standard use of Plerixafor strictly within a standard re-mobilization scheme following failure of the first mobilization (SSP), and iii) the standard (re-)mobilization scheme without Plerixafor (SSNP). METHODS: Decision tree models were built to compare clinical outcomes and direct costs from the payer's perspective in all three strategies. They were populated with efficacy resource use data from a first-of-a-kind patient registry of all patients with plerixafor administered (nϭ93) in 6 Czech centres. RESULTS: The success rates and costs for POD, SSP and SSNP were 94. 9% and EUR 5,736, 94.7% and EUR 6,416, and 84.7% and EUR 4,775, respectively. The direct cost per successfully treated average patient was EUR 6,046, EUR 6,776 and EUR 5,641, respectively. The cost of the first mobilization attempt with G-CSF was EUR 3,905 per patient. The cost of re-mobilization of a poor mobilizer was EUR 4,629 with G-CSF only and EUR 13,354 if plerixafor was added. The total cost of plerixafor used on-demand in the sub-cohort of poor mobilisers was EUR 13,645. CONCLUSIONS: Plerixafor substantially increases chances of success and its use is more cost-effective "on demand" during early mobilization than in subsequent re-mobilization.
OBJECTIVES:
To evaluate the cost-effectiveness of icatibant [Shire HGT] 30 mg subcutaneous versus C1-esterase inhibitor concentrate (C1-INH) [CSL-Behring] 20 IU/kg intravenous for moderate to severe attacks of hereditary angioedema (HAE) types I and II in the UK setting. METHODS: A probabilistic cost-utility model was developed over a time horizon of 96 h (the duration of a single acute attack). Comparisons were made for therapy administered at home and in hospital. Qualityadjusted life years (QALYs) were estimated by combining the time to onset of symptom relief with utility weights for the health states before and after onset of symptom relief. Clinical evidence and other model parameters were identified by systematic review. An indirect comparison using previously published methods was conducted. Costs relating to drug acquisition; administration; repeat injections; monitoring and supportive care; hepatitis A and B vaccinations for C1-INH; self-administration training; and adverse events were considered. Probabilistic and univariate sensitivity analyses were conducted. RESULTS: The indirect analysis suggested a non-significant trend towards a reduced time to symptom relief for icatibant when compared with C1-INH. In the economic analysis, there was a nonsignificant inter-treatment difference in estimated QALYs per attack, equivalent to ϳ0.75 quality-adjusted life hours in icatibant's favour. In the base-case analysis (SmPC dosing and NHS list price), total costs per attack were estimated as £1,577 for icatibant and £2,169 for C1-INH; a saving of £592 (95%CI: £394 -£715) per attack with icatibant. CONCLUSIONS: This is one of the first comparative health economic models presented for HAE. The systematic approach to data identification and analysis led to successful submissions to SMC and AWMSG in this orphan indication. The analysis demonstrated that icatibant reduces costs versus C1-INH (20 IU/kg at SmPC dosing) when treating acute HAE attacks in the UK setting.
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COST-EFFECTIVENESS OF FEBUXOSTAT IN MANAGING HYPERURICEMIA IN GOUT PATIENTS IN SPAIN
Cuesta M, Pérez Alcántara F, Brosa M Oblikue Consulting, Barcelona, Spain OBJECTIVES: To estimate the cost-effectiveness of febuxostat compared with allopurinol in the treatment of hyperuricaemia in patients with chronic gout when urate deposition has already occurred. METHODS: A Markov model was developed to estimate costs, clinical outcomes, and QALYs for patients with hyperuricaemia and chronic gout. Febuxostat 80 mg/120 mg as first line therapy (with or without allopurinol as second line therapy) and as second line therapy (after first line allopurinol) was compared to current standard therapy, i.e. allopurinol 300 mg daily with no second line treatment. A dichotomous sUA response/no response outcome after the first 3 months of each active treatment was used to decide when patients switched to a second line treatment. The definition of sUA response was applied using a target sUA level of Ͻ 6.0 mg/dL which was based on the latest EULAR guidelines. Efficacy data (sUA levels) were derived from febuxostat Phase III trials (APEX, FACT). Unit costs were derived from official tariffs (€2009). 3% discount rate and 5-year time horizon was applied in the primary analysis. Sensitivity analyses were performed to assess the impact of variations on all model inputs and subgroup analyses (patients intolerant to allopurinol, or patients having mild-moderate renal impairment). Analyse was carried out from the National Health System perspective. RESULTS: The addition of febuxostat in any therapeutic strategy (both as first-line or second line treatment) is an efficient option, with incremental costeffectiveness ratios (ICER) compared with standard allopurinol 300 mg ranging from 3,800 € to 6,600 €. The cost-effectiveness results show that the two-step twodrug treatment strategies provide additional QALY benefit over the single-step single-drug treatment strategies. CONCLUSIONS: Results suggest that febuxostat is a cost-effective treatment in Spain for the management of hyperuricemia in patients with gout, showing ICERs far below the commonly cited efficiency threshold in Spain (30,000€/QALY). 
PSY29 TITLE: THE CHALLENGE OF CONDUCTING A PROSPECTIVE ECONOMIC EVALUATION OF A PHARMACOGENETIC TEST
OBJECTIVES:
A pharmacogenetic test (PGx) prior to prescribing azathioprine is available to identify patients at increased risk of dose-limiting side effects (eg. neutropaenia). This study had two aims (1) to evaluate whether the PGx is a cost effective use of health care resources and (2) to understand whether it is feasible to conduct a prospective economic trial of a PGx. METHODS: An economic evaluation integrated into a prospective, pragmatic, multi-centre (nϭ19) randomised controlled trial (RCT) compared (i) PGx with standard care (SC); 167 patients to (ii) SC comprising step-wise dose escalation of azathioprine; 166 patients. The perspective of the UK NHS, with 4-month time horizon, was used to be consistent with the original RCT (the TARGET study). Individual patient-level data on resource use (primary care, secondary care, drug-use, monitoring tests) and health status (EQ-5D) were collected for all recruited patients. Quality adjusted life years (QALYs) were calculated using UK-population EQ-5D tariffs. Unit costs were collected from national sources (price year: 2010). GLM regression models estimated incremental costs and QALYs. Uncertainty in the results was characterised through the use of non-parametric bootstraps and cost-effectiveness acceptability curves with oneway sensitivity analysis to explore methodological assumptions. RESULTS: PGx with SC was £436 (95% CI: -£1064, £119) less expensive but with fewer QALYs 0.00451 (95% CI: -0.01291, 0.00430) compared with only SC. Analysis indicated that clinicians did not follow azathioprine prescribing recommendations in the PGx arm, resulting in no difference in the dosage of azathioprine between the two arms at 4-months (pϭ0.25). Uncertainty in the results was driven by problems associated with prescribing behaviour as well as low power due to small sample size. CONCLUSIONS: The analysis found that PGx could be a cost-effective use of resources but key uncertainties remain, driven by the challenge of conducting a trial-based economic evaluation of a diagnostic PGx.
PSY30
COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
Valencia-Mendoza A 1 , Hernández-Garduño A 2 , Puig A 3 1 Janssen de Mexico, Mexico, DF, D.F., Mexico, 2 Janssen de Mexico, Mexico, D.F., Mexico, 3 Janssen Pharmaceuticals, Raritan, NJ, USA OBJECTIVES: To evaluate the cost-effectiveness of ustekinumab for the treatment of moderate-to-severe plaque psoriasis from the perspective of the public health care institutions in Mexico. METHODS: A Markov model was developed to simulate patients with moderate-to-severe plaque psoriasis. Biologic therapies compared were ustekinumab 45mg every 12 weeks, adalimumab 40mg every two weeks, etanercept 50mg twice a week and infliximab 5mg/kg every eight weeks. Measured by the Psoriasis Area and Severity Index (PASI), clinical response was derived from the latest published meta-analysis. PASI response was translated into QALYs in two steps: (1) defining the correlation between PASI levels and the Dermatology Life Quality Index (DLQI); and (2) using a formula to predict utility from DLQI score derived from a mapping exercise of the DLQI with the EQ-5D. The model considered expenditure on drugs, monitoring visits, adverse events and inpatient stays. Costs were obtained from Mexican public institutions. Health and economic outcomes were estimated over a 10-year time horizon with cycle length of 12 weeks. Cost and QALYs were discounted at 5% annually. RESULTS: For patients with body weigh above 60kg, Adalimumab was an extended dominated strategy by ustekinumab. For these patients, the incremental cost-per-QALY of ustekinumab vs etanercept was US$19,542, whereas the incremental cost-per-QALY of infliximab vs ustekinumab was US$87,745. For patients with body weigh below 60kg, infliximab is more effective and less costly than adalimumab and ustekinumab, while the incremental cost-per-QALY vs etanercept was US$5,202. CONCLUSIONS: Considering the GDP per-capita of Mexico in 2010 (US$9,123), and according to the WHO Commission on Macroeconomics and Health, in patients with body weigh above 60kg ustekinumab is a cost-effective strategy (Յ3xGDP per-capita /QALY gained); while in patients with body weigh below 60kg infliximab is a highly cost-effective strategy (Յ1xGDP per-capita/QALY gained). Probabilistic sensitivity analysis results did not change the conclusions.
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